These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 18818310)

  • 1. AP4 encodes a c-MYC-inducible repressor of p21.
    Jung P; Menssen A; Mayr D; Hermeking H
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15046-51. PubMed ID: 18818310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
    Seoane J; Le HV; Massagué J
    Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter.
    Wu S; Cetinkaya C; Munoz-Alonso MJ; von der Lehr N; Bahram F; Beuger V; Eilers M; Leon J; Larsson LG
    Oncogene; 2003 Jan; 22(3):351-60. PubMed ID: 12545156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of c-myc regulation in Zta-mediated induction of the cyclin-dependent kinase inhibitors p21 and p27 and cell growth arrest.
    Rodriguez A; Jung EJ; Yin Q; Cayrol C; Flemington EK
    Virology; 2001 Jun; 284(2):159-69. PubMed ID: 11384216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The c-MYC-AP4-p21 cascade.
    Jung P; Hermeking H
    Cell Cycle; 2009 Apr; 8(7):982-9. PubMed ID: 19270520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc.
    Wang LG; Liu XM; Fang Y; Dai W; Chiao FB; Puccio GM; Feng J; Liu D; Chiao JW
    Int J Oncol; 2008 Aug; 33(2):375-80. PubMed ID: 18636159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
    Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
    Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells.
    Horiguchi-Yamada J; Fukumi S; Saito S; Nakayama R; Iwase S; Yamada H
    Anticancer Res; 2002; 22(6C):3827-32. PubMed ID: 12553001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD.
    Chi XZ; Yang JO; Lee KY; Ito K; Sakakura C; Li QL; Kim HR; Cha EJ; Lee YH; Kaneda A; Ushijima T; Kim WJ; Ito Y; Bae SC
    Mol Cell Biol; 2005 Sep; 25(18):8097-107. PubMed ID: 16135801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
    Marcotte R; Chen JM; Huard S; Wang E
    J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel antioxidant 3-O-Caffeoyl-1-methylquinic acid enhances ultraviolet A-mediated apoptosis in immortalized HaCaT keratinocytes via Sp1-dependent transcriptional activation of p21(WAF1/Cip1).
    Kweon MH; Afaq F; Bhat KM; Setaluri V; Mukhtar H
    Oncogene; 2007 May; 26(24):3559-71. PubMed ID: 17146435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-cycle progression is not essential for c-Myc to block differentiation.
    Ryan KM; Birnie GD
    Oncogene; 1997 Jun; 14(23):2835-43. PubMed ID: 9190900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1.
    Vigneron A; Roninson IB; Gamelin E; Coqueret O
    Cancer Res; 2005 Oct; 65(19):8927-35. PubMed ID: 16204065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repression of the human immunodeficiency virus type-1 long terminal repeat by the c-Myc oncoprotein.
    Stojanova A; Caro C; Jarjour RJ; Oster SK; Penn LZ; Germinario RJ
    J Cell Biochem; 2004 May; 92(2):400-13. PubMed ID: 15108364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
    Cosgrave N; Hill AD; Young LS
    J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mad4 is regulated by a transcriptional repressor complex that contains Miz-1 and c-Myc.
    Kime L; Wright SC
    Biochem J; 2003 Feb; 370(Pt 1):291-8. PubMed ID: 12418961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors.
    Schuldiner O; Benvenisty N
    Oncogene; 2001 Aug; 20(36):4984-94. PubMed ID: 11526483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
    Choe C; Chen N; Sawadogo M
    Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents.
    Amundson SA; Zhan Q; Penn LZ; Fornace AJ
    Oncogene; 1998 Oct; 17(17):2149-54. PubMed ID: 9811446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation.
    Vaqué JP; Fernández-García B; García-Sanz P; Ferrandiz N; Bretones G; Calvo F; Crespo P; Marín MC; León J
    Mol Cancer Res; 2008 Feb; 6(2):325-39. PubMed ID: 18314492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.